header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.


Octapharma USA Funds Only National Camp Exchange Program for Bleeding Disorders Community Camps


Interested Camp Professionals Should Apply by May 30th for Grant Funded Program

Chris Bombardier, First Hemophiliac to Climb the Seven Summits, Joins Octapharma USA at HFA Annual Symposium in Cleveland


Mountain Climber Will Discuss Mount Everest Climb, Upcoming Documentary One-on-One With Visitors of Octapharma Booth

Octapharma USA Grant Supports National Conference for Type 3 von Willebrand Disease Patients


‘Making the Connection’ will be held June 22 – 25 in Palm Beach Gardens, Florida

Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million


Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion...

Octapharma Support Enables Bombardier to Climb Mount Vinson, Becoming First Hemophiliac to Ascend the Seven Summits


Octapharma Partnership with Mountain Climber will Culminate with Release of Documentary Bombardier Blood Later This Year

Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A


Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study...